New cytotoxic agents: a review of the literature.
The goal of treatment for patients with advanced cancer is to prolong survival, control symptoms, and reduce disease-related complications. Despite the introduction of many cytotoxic agents during the past decade, only modest improvement in survival has been achieved. In order to urgently improve these situations, new cytotoxic agents as well as molecular-targeted agents are now under investigation. In this article, we reviewed the latest information regarding antitumor activity, toxicity, pharmacokinetics, and clinical application of the new cytotoxic agents.
Hotta
Katsuyuki
K
Health and Environmental Center, Okayama University, 2-1-1, Tsushimanaka, Okayama 700-8530, Japan. khotta@md.okayama-u.ac.jp
Ueoka
Hiroshi
H
D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating; D002166:Camptothecin / Q000031:analogs & derivatives; D006801:Humans; D016896:Treatment Outcome; D050257:Tubulin Modulators
D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D050257:Tubulin Modulators; D002166:Camptothecin